New York, New York, United States The main office of represented Corporate Investor is situated in the New York. The venture was found in North America in United States.
The important activity for fund was in 2019. The higher amount of exits for fund were in 2019. Comparing to the other companies, this Cormorant Capital performs on 4 percentage points more the average number of lead investments. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of more than 100 millions dollars.
We can highlight the next thriving fund investment areas, such as Life Science, Biopharma. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline BridgeBio, CMAB BioPharm, Cabaletta Bio
The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Cormorant Capital, startups are often financed by Third Rock Ventures, The Column Group, Kohlberg Kravis Roberts. The meaningful sponsors for the fund in investment in the same round are Viking Global Investors, Perceptive Advisors, Kohlberg Kravis Roberts.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Amalfi Capital | China, Shanghai |
| Cogito Capital | Canada, Ontario, Toronto |
| Coventry University Enterprise | - |
| Goodpatch | Japan, Tokyo |
| Hillside Capital | New York, New York, United States |
| Manjinghua | China, Guangdong, Shenzhen |
| Revel Partners | New York, New York, United States |
| Solace Capital Partners | California, Los Angeles, United States |
| Sprout Tokyo | Japan, Tokyo |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Terremoto Biosciences | $175M | 02 Nov 2023 | San Francisco, California, United States | ||
Shoreline Biosciences | $43M | 07 Feb 2021 | San Diego, California, United States | ||
Revolution Medicines | $100M | 09 Jul 2019 | Redwood City, California, United States | ||
Satsuma Pharmaceuticals | $62M | 24 Apr 2019 | South San Francisco, California, United States | ||
Cabaletta Bio | $50M | 03 Jan 2019 | Philadelphia, Pennsylvania, United States | ||
CMAB BioPharm | $34M | 02 Apr 2018 | Gusu District, Jiangsu, China | ||
BridgeBio | $135M | 13 Sep 2017 | Palo Alto, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Terremoto Biosciences | $175M | 02 Nov 2023 | San Francisco, California, United States | ||
Shoreline Biosciences | $43M | 07 Feb 2021 | San Diego, California, United States | ||
Revolution Medicines | $100M | 09 Jul 2019 | Redwood City, California, United States | ||
Satsuma Pharmaceuticals | $62M | 24 Apr 2019 | South San Francisco, California, United States | ||
Cabaletta Bio | $50M | 03 Jan 2019 | Philadelphia, Pennsylvania, United States | ||
CMAB BioPharm | $34M | 02 Apr 2018 | Gusu District, Jiangsu, China | ||
BridgeBio | $135M | 13 Sep 2017 | Palo Alto, California, United States |
